We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian Medical (VAR) Signs Distribution Deal with Bionix
Read MoreHide Full Article
Palo Alto, CA-based manufacturer of medical devices and software, Varian Medical Systems, Inc. , announced that it has signed a distribution agreement with Toledo, OH-based Bionix Radiation Therapy. Per the agreement, Varian Medical would distribute Bionix’s propreitory brachytherapy applicators. Varian will market the Bionix Esophageal Applicator (E-App) and the Anorectal Applicator (AR-1) in North America.
Of the above two applicators, E-App is a disposable brachytherapy applicator. It is designed specifically for the treatment of cancers. The E-App features five independently operable balloons that maintain the central position of the source catheter in both straight and curved anatomy. This allows for closer proximity of the target to the source while maintaining distance from healthy tissue.
The second applicator, AR-1 is a disposable brachytherapy applicator. It is designed specifically for the treatment of anal and rectal cancers. The dual balloon design of the AR-1 allows exophytic tumors to press closer to the source catheter. This creates the ability to deliver a very high dose to the tumor, while sparing healthy tissue.
Future Trend
We note that the global radiotherapy market is expected to reach a worth of $7,544.8 million by 2020, at a CAGR of 6.2%. Taking the bountiful prospects in the global niche space into consideration, the latest development should boost investor’s confidence.
Share Price Performance
A promising portfolio combined with robust initiatives has been favoring this Zacks Rank #3 (Hold) company, which has delivered positive earnings surprise in 12 of the last 14 quarters. We note that shares of Varian Medical have declined 0.2% over the past three months against the broader industry, which grew 0.5% in the same time frame.
Our Take
Varian Medical operates in a technology-driven environment where success depends on innovation and frequent product updates. The company has been successful on the R&D front as evident from year-over-year expansion in its top line. The company has approximately $1 billion revenue opportunity from its various Oncology and Imaging Component products over the next five years.
Apart from enjoying a dominant market share in conventional radiotherapy, we believe that proton therapy holds significant promise for Varian Medical. This is because ProBeam Compact proton therapy system is superior to other external beam radiotherapies in precisely locating cancerous tumors and cause lesser side-effects to surrounding tissues. Proton therapy system uses the same interface used by the company in its TrueBeam platform.
Finally, the company’s strong overseas presence is expected to enable it to leverage this opportunity in emerging markets. In line with growing demand for cancer treatment in overseas markets, Varian Medical’s sales, in Europe, Africa and particularly Asia, are growing at a faster rate than in the domestic market.
Do Medical Stocks Interest You? Check These
Investors may consider better-ranked stocks from the same sector such as Edwards Lifesciences Corporation (EW - Free Report) , Fresenius Medical Care Corporation (FMS - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Notably, the stock has returned 5.5% over the last three months.
Fresenius Medical yielded a strong return of 8.3% year to date. The stock has a long-term expected earnings growth rate of 10%.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. Additionally, the stock represents an impressive one-year return of 39.3%.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today. Learn more >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Varian Medical (VAR) Signs Distribution Deal with Bionix
Palo Alto, CA-based manufacturer of medical devices and software, Varian Medical Systems, Inc. , announced that it has signed a distribution agreement with Toledo, OH-based Bionix Radiation Therapy. Per the agreement, Varian Medical would distribute Bionix’s propreitory brachytherapy applicators. Varian will market the Bionix Esophageal Applicator (E-App) and the Anorectal Applicator (AR-1) in North America.
Of the above two applicators, E-App is a disposable brachytherapy applicator. It is designed specifically for the treatment of cancers. The E-App features five independently operable balloons that maintain the central position of the source catheter in both straight and curved anatomy. This allows for closer proximity of the target to the source while maintaining distance from healthy tissue.
The second applicator, AR-1 is a disposable brachytherapy applicator. It is designed specifically for the treatment of anal and rectal cancers. The dual balloon design of the AR-1 allows exophytic tumors to press closer to the source catheter. This creates the ability to deliver a very high dose to the tumor, while sparing healthy tissue.
Future Trend
We note that the global radiotherapy market is expected to reach a worth of $7,544.8 million by 2020, at a CAGR of 6.2%. Taking the bountiful prospects in the global niche space into consideration, the latest development should boost investor’s confidence.
Share Price Performance
A promising portfolio combined with robust initiatives has been favoring this Zacks Rank #3 (Hold) company, which has delivered positive earnings surprise in 12 of the last 14 quarters. We note that shares of Varian Medical have declined 0.2% over the past three months against the broader industry, which grew 0.5% in the same time frame.
Our Take
Varian Medical operates in a technology-driven environment where success depends on innovation and frequent product updates. The company has been successful on the R&D front as evident from year-over-year expansion in its top line. The company has approximately $1 billion revenue opportunity from its various Oncology and Imaging Component products over the next five years.
Apart from enjoying a dominant market share in conventional radiotherapy, we believe that proton therapy holds significant promise for Varian Medical. This is because ProBeam Compact proton therapy system is superior to other external beam radiotherapies in precisely locating cancerous tumors and cause lesser side-effects to surrounding tissues. Proton therapy system uses the same interface used by the company in its TrueBeam platform.
Finally, the company’s strong overseas presence is expected to enable it to leverage this opportunity in emerging markets. In line with growing demand for cancer treatment in overseas markets, Varian Medical’s sales, in Europe, Africa and particularly Asia, are growing at a faster rate than in the domestic market.
Do Medical Stocks Interest You? Check These
Investors may consider better-ranked stocks from the same sector such as Edwards Lifesciences Corporation (EW - Free Report) , Fresenius Medical Care Corporation (FMS - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Notably, Edwards Lifesciences and Fresenius Medical sport a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Notably, the stock has returned 5.5% over the last three months.
Fresenius Medical yielded a strong return of 8.3% year to date. The stock has a long-term expected earnings growth rate of 10%.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. Additionally, the stock represents an impressive one-year return of 39.3%.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today. Learn more >>